https://www.selleckchem.com/products/yo-01027.html
To assess the efficacy of a treat-and-extend strategy with intravitreal ranibizumab for radiation-related macular edema. Forty eyes with radiation-induced macular edema and decreased visual acuity were enrolled in the phase IIb, prospective clinical trial and randomized into 3 cohorts (A) monthly ranibizumab, ( monthly ranibizumab with targeted retinal photocoagulation (TRP), or (C) as-needed ranibizumab and TRP. In year 2, all subjects entered a treat-and-extend protocol for ranibizumab. The primary outcome measure was mean change i
Curtir
Comentario
Compartilhar
